Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial
The Journal of Clinical Endocrinology & Metabolism · 16.06.2023 · 108 (7) · 1676-1685
DOI: 10.1210/clinem/dgad014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 14.01.2023. Verfasst von Jennifer L Miller und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, University of Florida College of Medicine, Gainesville, Florida 32608, USA. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, COVID-19. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, Soleno Therapeutics.
Abstract (Originalsprache)
Context
Prader-Willi syndrome (PWS) is a rare neurobehavioral-metabolic disease caused by the lack of paternally expressed genes in the chromosome 15q11-q13 region, characterized by hypotonia, neurocognitive problems, behavioral difficulties, endocrinopathies, and hyperphagia resulting in severe obesity if not controlled.
Objective
The primary end point was change from baseline in hyperphagia using the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). Other end points included Global Impression Scores, and changes in body composition, behaviors, and hormones.
Methods
In DESTINY PWS, a 13-week, randomized, double-blind, placebo-controlled, phase 3 trial, 127 participants with PWS aged 4 years and older with hyperphagia were randomly assigned 2:1 to diazoxide choline extended-release tablet (DCCR) or placebo.
Results
DCCR did not significantly improve hyperphagia (HQ-CT least-square mean (LSmean) [SE] −5.94 [0.879] vs −4.27 [1.145]; P = .198), but did so in participants with severe hyperphagia (LSmean [SE] −9.67 [1.429] vs −4.26 [1.896]; P = .012). Two of 3 secondary end points were improved (Clinical Global Impression of Improvement [CGI-I]; P = .029; fat mass; P = .023). In an analysis of results generated pre-COVID, the primary (HQ-CT; P = .037) and secondary end points were all improved (CGI-I; P = .015; Caregiver Global Impression of Change; P = .031; fat mass; P = .003). In general, DCCR was well tolerated with 83.3% in the DCCR group experiencing a treatment-emergent adverse event and 73.8% in the placebo group (not significant).
Conclusion
DCCR did not significantly improve hyperphagia in the primary analysis but did in participants with severe baseline hyperphagia and in the pre-COVID analysis. DCCR treatment was associated with significant improvements in body composition and clinician-reported outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology, University of Florida College of Medicine, Gainesville, Florida 32608, USA.
- Queen Mary University London, London E1 4NS, UK; Barts Health NHS Trust-Royal London Children's Hospital, London E1 1FR, UK.
- Chelsea and Westminster Hospital, London, UK.
- US Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.
- Endocrinology, Seattle Children's Hospital, Seattle, Washington 98105, USA.
- Endocrinology, Nationwide Children's Hospital, Columbus, Ohio 43205, USA.
ORCID-Profile: Jennifer L Miller
Förderung
- NICHD NIH HHS
- Soleno Therapeutics
Zitieren
APA
Miller, J. L., Gevers, E., Bridges, N., Yanovski, J. A., Salehi, P., Obrynba, K. S., Felner, E. I., Bird, L. M., Shoemaker, A. H., Angulo, M., Butler, M. G., Stevenson, D., Abuzzahab, J., Barrett, T., Lah, M., Littlejohn, E., Mathew, V., Cowen, N. M., Bhatnagar, A., & DESTINY PWS Investigators (2023). Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Endocrinology & Metabolism, 108(7), 1676-1685. https://doi.org/10.1210/clinem/dgad014
Vancouver
Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, et al. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. 2023;108(7):1676-1685. doi:10.1210/clinem/dgad014
BibTeX
@article{Miller2023,
author = {Miller, Jennifer L and Gevers, Evelien and Bridges, Nicola and Yanovski, Jack A and Salehi, Parisa and Obrynba, Kathryn S and Felner, Eric I and Bird, Lynne M and Shoemaker, Ashley H and Angulo, Moris and Butler, Merlin G and Stevenson, David and Abuzzahab, Jennifer and Barrett, Timothy and Lah, Melissa and Littlejohn, Elizabeth and Mathew, Verghese and Cowen, Neil M and Bhatnagar, Anish and DESTINY PWS Investigators, DESTINY PWS Investigators},
title = {Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {7},
pages = {1676--1685},
doi = {10.1210/clinem/dgad014}
}
EUVIMED